← All candidates
One insider buy in the last year — $250.0K in all.
39 filings on record.
VERAVera Therapeutics, Inc.
NasdaqGM · Healthcare · $2.53B
$35.05
+4.32% · Sep 11
One insider buy in the last year — $250.0K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 20 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.53B
Float
52.4M
73% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Enright Patrick G
Bought $2.91M on Jun 23 — 139,595 sh @ $20.87, held indirect, 3.9% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
34 more transactions on Pro →Context
Wall St
$77.14 avg target
+120.1% vs today · 14 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
1 of 4 quarters beat
Q2 '26−$1.52 act+$0.07
Q4 '25−$1.39 act−$0.12
Q3 '25−$1.26 act−$0.08
Q2 '25−$1.20 act−$0.58
Coverage
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets LaunchMarketBeat · 07-11Is FDA Accelerated Approval Of TRUTAKNA Transforming The Investment Case For Vera Therapeutics (VERA)?Simply Wall St. · 07-10Vera Therapeutics (VERA) Could Be 92% Below Fair Value After FDA ApprovalSimply Wall St. · 07-10Vera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% Run
The file stays open
39 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice